Par Equity led the Series A round with participation from Mercia, Triplepoint, SIS Ventures, Scottish Enterprise and the MacLeod Family Trust.
"Our technology is already making a significant impact within counter terror and child sexual abuse investigations in the UK, and we're excited to build on this momentum in mainland Europe and the US. We've built a great network of partners to support our ambitious growth plans, and our team will double in size during each of the next two years to support this growth."
The seed follow-on round from existing backers Mercia and NorthStar Ventures will fund international expansion in the US and accelerate product launches.
"Over the last two years Newcells has made great progress in bringing innovative products and services to market that have delivered value to our global pharmaceutical customers. Whether it be in understanding how new drugs interact with the kidney or the retina, our scientists have produced data that has helped lower the risk of early drug discovery projects. The input and support of Mercia and NorthStar has been invaluable in driving forward the business. Our vision is to bring the best in vitro biology to market, improving the productivity of drug discovery and development"
The medtech start-up has raised £2.2m from ACF Investors and Mercia to fund its American market launch and product pipeline.
"I am really pleased to work with ACF for a second time to bring their support to Axis Spine. It is a great example of the UK ecosystem supporting fantastic entrepreneur-led medtech companies and I am delighted to assist Jon and the Axis team take their superior products to market and to build out the underlying platform."
